BeiGene Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BeiGene stock.
View analyst ratings for BeiGene or view top-rated stocks.

6 Wall Street research analysts have issued 12-month price objectives for BeiGene's shares. Their BGNE stock forecasts range from $177.00 to $431.00. On average, they anticipate BeiGene's stock price to reach $315.33 in the next year. This suggests a possible upside of 91.2% from the stock's current price.
View analysts' price targets for BeiGene or view top-rated stocks among Wall Street analysts.

BeiGene's stock was trading at $270.93 at the beginning of 2022. Since then, BGNE shares have decreased by 39.1% and is now trading at $164.91.
View the best growth stocks for 2022 here.

BeiGene is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for BeiGene.

BeiGene, Ltd. (NASDAQ:BGNE) announced its quarterly earnings results on Thursday, May, 5th. The company reported ($4.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.52) by $0.28. The business earned $306.60 million during the quarter, compared to analyst estimates of $300.41 million. BeiGene had a negative trailing twelve-month return on equity of 40.10% and a negative net margin of 218.25%. The firm's revenue for the quarter was down 49.4% on a year-over-year basis.
View BeiGene's earnings history.

21 employees have rated BeiGene CEO John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among BeiGene's employees.

Some companies that are related to BeiGene include Regeneron Pharmaceuticals (REGN), Bayer Aktiengesellschaft (BAYRY), Takeda Pharmaceutical (TAK), Astellas Pharma (ALPMY), Royalty Pharma (RPRX), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Takeda Pharmaceutical (TKPYY), Genmab A/S (GNMSF), Genmab A/S (GMAB), Catalent (CTLT), Horizon Therapeutics Public (HZNP), Alnylam Pharmaceuticals (ALNY), UCB (UCBJF), Shiseido (SSDOY) and BioMarin Pharmaceutical (BMRN).
View all of BGNE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Square (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

(BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

BeiGene's stock is owned by many different retail and institutional investors. Top institutional investors include Capital International Investors (6.84%), Baillie Gifford & Co. (4.00%), Primecap Management Co. CA (3.61%), Temasek Holdings Private Ltd (2.88%), Invesco Ltd. (2.65%) and BlackRock Inc. (2.63%). Company insiders that own BeiGene stock include Amgen Inc, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends for BeiGene.

BGNE stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Invesco Ltd., Fiera Capital Corp, USS Investment Management Ltd, State Street Corp, Matthews International Capital Management LLC, New York State Common Retirement Fund, and Baillie Gifford & Co.. Company insiders that have sold BeiGene company stock in the last two years include Bros Advisors Lp Baker, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Timothy Yung-Cheng Chen, Xiaobin Wu, and Xiaodong Wang.
View insider buying and selling activity for BeiGene or view top insider-selling stocks.

BGNE stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Bank of America Corp DE, Bridgewater Associates LP, Zeal Asset Management Ltd, Capital Group International Inc. CA , Capital Group Private Client Services Inc., BlackRock Inc., and Goldman Sachs Group Inc.. Company insiders that have bought BeiGene stock in the last two years include Amgen Inc, and Ltd Beigene.
View insider buying and selling activity for BeiGene or or view top insider-buying stocks.

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BGNE stock can currently be purchased for approximately $164.91.

BeiGene (NASDAQ:BGNE) has a market capitalization of $17.03 billion and generates $1.18 billion in revenue each year. The company earns $-1.41 billion in net income (profit) each year or ($20.090010) on an earnings per share basis.

BeiGene employs 8,200 workers across the globe.

BeiGene was founded in 2010.

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The official website for BeiGene is www.beigene.com. The company can be reached via phone at 861085148500 or via email at [email protected].